Background Ischemic disease is one of the leading causes of death in the world. In order to further study gene therapy for ischemic disease, we constructed a recombinant plasmid for co-expression of human angiopoieti...Background Ischemic disease is one of the leading causes of death in the world. In order to further study gene therapy for ischemic disease, we constructed a recombinant plasmid for co-expression of human angiopoietin-1 and vascular endothelial growth factor 165(VEGF165) gene in adeno-associated virus (AAV) gene delivery system. Methods Human angiopoietin 1 and VEGF165 gene were obtained using PCR. The upstream of angiopoietin 1 contained restriction enzyme site HindⅢ, and the downstream of angiopoietin 1 contained restriction enzyme site BamHⅠ. The upstream of VEGF165 contained restriction enzyme site BglⅡ, and the downstream of VEGF165 contained restriction enzyme site BamHⅠ. Using the multiple cloning sites (MCS) in plasmid pZero++ such as BamHⅠ, BglⅡ, HindⅢ, NotⅠ, XhoⅠ, XbaⅠ, SalⅠ, BspHⅠ, KspⅠ and the corresponding MCS in plasmid pAAV-MCS, angiopoietin 1 and VEGF165 gene were subcloned into pAAV-MCS. Results DNA sequencing revealed that the PCR- amplified angiopoietin 1 and VEGF165 were consistent with NCBI Gene Bank. The recombinant plasmid was identified using PCR and digestion, which proved to be consistent with our hypothesis. In recombinant plasmid, angiopoietin1 and VEGF possessed a CMV promoter and polyA terminator system respectively, thus assuring co-expression of the two genes. Conclusion Successful construction of AAV co-expression system for human angiopoietin 1 and VEGF165 gene will provide the foundation for gene therapy to cure severe ischemic disease.展开更多
基金TheprojectwassupportedbyNationalNatureScienceFoundationofChina (No 3 0 2 712 65 )
文摘Background Ischemic disease is one of the leading causes of death in the world. In order to further study gene therapy for ischemic disease, we constructed a recombinant plasmid for co-expression of human angiopoietin-1 and vascular endothelial growth factor 165(VEGF165) gene in adeno-associated virus (AAV) gene delivery system. Methods Human angiopoietin 1 and VEGF165 gene were obtained using PCR. The upstream of angiopoietin 1 contained restriction enzyme site HindⅢ, and the downstream of angiopoietin 1 contained restriction enzyme site BamHⅠ. The upstream of VEGF165 contained restriction enzyme site BglⅡ, and the downstream of VEGF165 contained restriction enzyme site BamHⅠ. Using the multiple cloning sites (MCS) in plasmid pZero++ such as BamHⅠ, BglⅡ, HindⅢ, NotⅠ, XhoⅠ, XbaⅠ, SalⅠ, BspHⅠ, KspⅠ and the corresponding MCS in plasmid pAAV-MCS, angiopoietin 1 and VEGF165 gene were subcloned into pAAV-MCS. Results DNA sequencing revealed that the PCR- amplified angiopoietin 1 and VEGF165 were consistent with NCBI Gene Bank. The recombinant plasmid was identified using PCR and digestion, which proved to be consistent with our hypothesis. In recombinant plasmid, angiopoietin1 and VEGF possessed a CMV promoter and polyA terminator system respectively, thus assuring co-expression of the two genes. Conclusion Successful construction of AAV co-expression system for human angiopoietin 1 and VEGF165 gene will provide the foundation for gene therapy to cure severe ischemic disease.
